Original Literature | Model OverView |
---|---|
Publication
Title
Anti-inflammatory actions of PPAR ligands: new insights on cellular andmolecular mechanisms.
Affiliation
Biomedical Sciences Division, University of California, Riverside, Riverside, CA92521-0121, USA. daniel.straus@ucr.edu
Abstract
The peroxisome proliferator-activated receptors (PPARalpha, -gamma, and-beta/delta) are nuclear receptors with distinct patterns of expression in manycell types both within and outside the immune system. PPAR ligands haveanti-inflammatory activity in a variety of mouse models for acute and chronicinflammation. In macrophages, PPARgamma ligands repress expression of a subsetof Toll-like receptor (TLR) target genes by a molecular mechanism termedligand-dependent transrepression. In chronic inflammation, ligand-boundPPARalpha represses production of IFNgamma and IL-17 by CD4(+) T cells, andPPARgamma ligands modulate dendritic cell function to elicit the development ofanergic CD4(+) T cells. PPAR ligands also repress expression of cell adhesionmolecules on endothelial cells and the secretion of chemokines by epithelial andother cells, decreasing the recruitment of leukocytes to the site ofinflammation. The anti-inflammatory activity of PPAR ligands in mouse modelssuggests their possible use for treating human inflammatory and autoimmunediseases.
PMID
17981503
|
Entity
RelA-p65
--
MO000000193
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m166
10
infinite
0
TRANSPATH | MO000000193 |
--
TNF-alpha
--
MO000000289
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m230
10
infinite
0
InterPro | IPR003636 |
TRANSPATH | MO000000289 |
--
p50:RelA-p65
--
MO000016632
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m1617
10
infinite
0
TRANSPATH | MO000016632 |
--
CXCR3
--
MO000019843
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m4372
10
infinite
0
InterPro | IPR000276 |
TRANSPATH | MO000019843 |
--
SUMO-1
--
MO000019971
cso30:c:Protein
cso30:i:CC_CellComponent
--
--
csml-variable:Double
m4499
10
infinite
0
InterPro | IPR000626 |
TRANSPATH | MO000019971 |
--
Ubc9
--
MO000019972
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m4500
10
infinite
0
TRANSPATH | MO000019972 |
--
glucocorticoids
--
MO000021732
cso30:c:Protein
cso30:i:CC_CellComponent
--
--
csml-variable:Double
m6069
10
infinite
0
TRANSPATH | MO000021732 |
--
HDAC4
--
MO000042976
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m20760
10
infinite
0
TRANSPATH | MO000042976 |
--
--
e1
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane
--
--
--
csml-variable:Double
m1
0
infinite
0
--
CXCL1
--
e10
cso30:c:mRNA
cso30:i:CC_Nucleoplasm
--
--
csml-variable:Double
m10
0
infinite
0
--
csml-variable:Double
m11
0
infinite
0
--
PPAR-alpha:RXR:PPRE
--
e12
cso30:c:Complex
cso30:i:CC_Nucleoplasm
--
--
csml-variable:Double
m12
0
infinite
0
--
Troglitazone
--
e13
cso30:c:SmallMolecule
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m13
0
infinite
0
--
PPAR-gamma
--
e14
cso30:c:Protein
cso30:i:CC_Nucleoplasm
--
csml-variable:Double
m14
0
infinite
0
--
PPAR-gamma:Troglitazone
--
e15
cso30:c:Complex
cso30:i:CC_Nucleoplasm
--
csml-variable:Double
m15
0
infinite
0
--
GW0742
--
e16
cso30:c:SmallMolecule
cso30:i:CC_Nucleoplasm
--
csml-variable:Double
m16
0
infinite
0
--
PPAR-delta
--
e17
cso30:c:Protein
cso30:i:CC_Nucleoplasm
--
csml-variable:Double
m17
0
infinite
0
--
NCoR:HDAC3:TBL1:TBLR1
--
e18
cso30:c:Complex
cso30:i:CC_Nucleoplasm
--
csml-variable:Double
m18
0
infinite
0
--
csml-variable:Double
m19
0
infinite
0
--
--
e2
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane_ExternalSideOfPlasmaMembrane_
--
--
--
csml-variable:Double
m2
0
infinite
0
--
LPS:TLR4
--
e20
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m20
0
infinite
0
--
p50:RelA-p65:IkappaB
--
e21
cso30:c:Complex
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m21
0
infinite
0
--
p50:RelA-p65:IkappaB{active}
--
e22
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m22
0
infinite
0
--
Degradants
--
e23
cso30:c:EntityBiological
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m23
0
infinite
0
--
19s proteosome
--
e25
cso30:c:Protein
cso30:i:CC_Nucleoplasm
--
--
csml-variable:Double
m25
0
infinite
0
--
NCoR:HDAC3:TBL1:TBLR1{ub}
--
e26
cso30:c:Complex
cso30:i:CC_Nucleoplasm
--
csml-variable:Double
m26
0
infinite
0
--
proteosome degradants
--
e27
cso30:c:EntityBiological
cso30:i:CC_Nucleoplasm
--
--
csml-variable:Double
m27
0
infinite
0
--
csml-variable:Double
m28
0
infinite
0
--
Activator complex
--
e29
cso30:c:Complex
cso30:i:CC_Nucleolus
--
--
csml-variable:Double
m29
0
infinite
0
--
--
e3
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
--
csml-variable:Double
m3
0
infinite
0
--
p50:RelA-p65:iNOS:Activator complex
--
e30
cso30:c:Complex
cso30:i:CC_Nucleoplasm
--
csml-variable:Double
m30
0
infinite
0
--
PPAR-gamma:troglitazone:SUMO-1
--
e31
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m31
0
infinite
0
--
NCoR:HDAC3:TBL1:TBLR1:PPAR-gamma:Troglitazone:SUMO-1
--
e32
cso30:c:Complex
cso30:i:CC_Nucleoplasm
--
--
csml-variable:Double
m32
0
infinite
0
--
PPAR-gamma:RCXR
--
e33
cso30:c:Complex
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m33
0
infinite
0
--
Inflammatory response gene mRNA
--
e34
cso30:c:mRNA
cso30:i:CC_Nucleoplasm
--
--
csml-variable:Double
m34
0
infinite
0
--
RelA-p65:PPAR-alpha
--
e35
cso30:c:Complex
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m35
0
infinite
0
--
PPARdelta:BCL-6
--
e36
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m36
0
infinite
0
--
PPARdelta:GW0742
--
e37
cso30:c:Complex
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m37
0
infinite
0
--
LXRalpha
--
e38
cso30:c:Protein
cso30:i:CC_Cytosol
--
csml-variable:Double
m38
0
infinite
0
--
LXRbeta
--
e39
cso30:c:Protein
cso30:i:CC_Cytosol
--
csml-variable:Double
m39
0
infinite
0
--
--
e4
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane_InternalSideOfPlasmaMembrane_
--
--
--
csml-variable:Double
m4
0
infinite
0
--
Ligand
--
e40
cso30:c:Protein
cso30:i:CC_Cytosol
--
csml-variable:Double
m40
0
infinite
0
--
LXRalpha:Ligand
--
e41
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m41
0
infinite
0
--
LXRbeta:Ligand
--
e42
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m42
0
infinite
0
--
SUMO-2
--
e43
cso30:c:Protein
cso30:i:CC_Cytosol
--
csml-variable:Double
m43
0
infinite
0
--
SUMO-3
--
e44
cso30:c:Protein
cso30:i:CC_Cytosol
--
csml-variable:Double
m44
0
infinite
0
--
LXRalpha:ligand:SUMO-2:SUMo-3
--
e45
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m45
0
infinite
0
--
LXRalpha:ligand:SUMO-2:SUMo-3:NCor co-repressor complex
--
e46
cso30:c:Complex
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m46
0
infinite
0
--
LXRbeta:ligand:SUMO-2:SUMo-3
--
e47
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m47
0
infinite
0
--
LXRbeta:ligand:SUMO-2:SUMo-3:NCor co-repressor complex
--
e48
cso30:c:Complex
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m48
0
infinite
0
--
GR ligand
--
e49
cso30:c:Protein
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m49
0
infinite
0
--
PPAR-alpha
--
e5
cso30:c:Protein
cso30:i:CC_Nucleoplasm
--
csml-variable:Double
m5
0
infinite
0
--
--
e50
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearEnvelopeLumen
--
--
--
csml-variable:Double
m50
0
infinite
0
--
--
e51
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearPore
--
--
--
csml-variable:Double
m51
0
infinite
0
--
--
e52
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearInnerMembrane
--
--
--
csml-variable:Double
m52
0
infinite
0
--
--
e53
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearLumen
--
--
--
csml-variable:Double
m53
0
infinite
0
--
--
e54
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearOuterMembrane
--
--
--
csml-variable:Double
m54
0
infinite
0
--
--
e55
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Nucleus
--
--
--
csml-variable:Double
m55
0
infinite
0
--
--
e56
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Nucleoplasm
--
--
--
csml-variable:Double
m56
0
infinite
0
--
--
e57
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearBody
--
--
--
csml-variable:Double
m57
0
infinite
0
--
--
e58
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Nucleolus
--
--
--
csml-variable:Double
m58
0
infinite
0
--
--
e59
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearEnvelope
--
--
--
csml-variable:Double
m59
0
infinite
0
--
PPAR-alpha:RXR
--
e6
cso30:c:Complex
cso30:i:CC_Nucleoplasm
--
--
csml-variable:Double
m6
0
infinite
0
--
--
e60
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Chromatin
--
--
--
csml-variable:Double
m60
0
infinite
0
--
--
e61
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearChromosome
--
--
--
csml-variable:Double
m61
0
infinite
0
--
--
e62
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearCentromere
--
--
--
csml-variable:Double
m62
0
infinite
0
--
Glucocorticoids:GR ligand
--
e63
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m63
0
infinite
0
--
Glucocorticoids:GRligand:RelA-p65
--
e64
cso30:c:Complex
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m64
0
infinite
0
--
IL-8
--
e65
cso30:c:mRNA
cso30:i:CC_Nucleoplasm
--
--
csml-variable:Double
m65
0
infinite
0
--
c-Jun:PPAR-alpha
--
e66
cso30:c:Complex
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m67
0
infinite
0
--
IL-12
--
e67
cso30:c:mRNA
cso30:i:CC_Nucleoplasm
--
--
csml-variable:Double
m68
0
infinite
0
--
CXCL10
--
e68
cso30:c:Protein
cso30:i:CC_Cytosol
--
csml-variable:Double
m69
0
infinite
0
--
Fenofibrate
--
e69
cso30:c:SmallMolecule
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m70
0
infinite
0
--
--
e7
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cell
--
--
--
csml-variable:Double
m7
0
infinite
0
--
PPAR-alpha:Fenofibrate
--
e70
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m71
0
infinite
0
--
Wy14643
--
e71
cso30:c:SmallMolecule
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m72
0
infinite
0
--
PPARalpha:Wy14643
--
e72
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m73
0
infinite
0
--
IL-17
--
e73
cso30:c:SmallMolecule
cso30:i:CC_Nucleoplasm
--
--
csml-variable:Double
m74
0
infinite
0
--
ICAM-2
--
e74
cso30:c:mRNA
cso30:i:CC_Nucleoplasm
--
--
csml-variable:Double
m75
0
infinite
0
--
CXCL8
--
e75
cso30:c:mRNA
cso30:i:CC_Nucleolus
--
--
csml-variable:Double
m76
0
infinite
0
--
GW7647
--
e76
cso30:c:SmallMolecule
cso30:i:CC_Extracellular
--
--
csml-variable:Double
m77
0
infinite
0
--
PPARgamma:GW7845
--
e77
cso30:c:Complex
cso30:i:CC_Cytoplasm
--
csml-variable:Double
m78
0
infinite
0
--
CXCL9
--
e78
cso30:c:mRNA
cso30:i:CC_Cytoplasm
--
csml-variable:Double
m79
0
infinite
0
--
CCL2
--
e79
cso30:c:mRNA
cso30:i:CC_Cytoplasm
--
--
csml-variable:Double
m80
0
infinite
0
--
--
e8
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cell_WithoutCellWall_
--
--
--
csml-variable:Double
m8
0
infinite
0
--
CCL4
--
e80
cso30:c:mRNA
cso30:i:CC_Nucleoplasm
--
--
csml-variable:Double
m81
0
infinite
0
--
CCL7
--
e81
cso30:c:mRNA
cso30:i:CC_Nucleoplasm
--
--
csml-variable:Double
m82
0
infinite
0
--
CCl12
--
e82
cso30:c:mRNA
cso30:i:CC_Nucleoplasm
--
--
csml-variable:Double
m83
0
infinite
0
--
CCL17
--
e83
cso30:c:mRNA
cso30:i:CC_Nucleoplasm
--
--
csml-variable:Double
m84
0
infinite
0
--
CCL19
--
e84
cso30:c:mRNA
cso30:i:CC_Cytoplasm
--
--
csml-variable:Double
m85
0
infinite
0
--
GW7647
--
e85
cso30:c:SmallMolecule
cso30:i:CC_Cytoplasm
--
--
csml-variable:Double
m86
0
infinite
0
--
PPAR-alpha:GW7647
--
e86
cso30:c:Complex
cso30:i:CC_Cytoplasm
--
csml-variable:Double
m87
0
infinite
0
--
CXCL10:CXCR3
--
e87
cso30:c:Complex
cso30:i:CC_Cytoplasm
--
--
csml-variable:Double
m88
0
infinite
0
--
CXCL9
--
e88
cso30:c:Protein
cso30:i:CC_Extracellular
--
--
csml-variable:Double
m89
0
infinite
0
--
CXCL9:CXCR3
--
e89
cso30:c:Complex
cso30:i:CC_Cytoplasm
--
--
csml-variable:Double
m90
0
infinite
0
--
--
e9
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cytoplasm
--
--
--
csml-variable:Double
m9
0
infinite
0
--
CXCL11
--
e90
cso30:c:mRNA
cso30:i:CC_Cytoplasm
--
--
csml-variable:Double
m91
0
infinite
0
--
CXCL11
--
e91
cso30:c:Protein
cso30:i:CC_Cytoplasm
--
--
csml-variable:Double
m92
0
infinite
0
--
CXCL11:CXCR3
--
e92
cso30:c:Complex
cso30:i:CC_Cytoplasm
--
--
csml-variable:Double
m93
0
infinite
0
--
ROS
--
e93
cso30:c:SmallMolecule
cso30:i:CC_PlasmaMembrane_InternalSideOfPlasmaMembrane_
--
--
csml-variable:Double
m94
0
infinite
0
--
PPARgamma
--
e94
cso30:c:mRNA
cso30:i:CC_Cytoplasm
--
csml-variable:Double
m95
0
infinite
0
--
PPAR-delta:ERK5
--
e95
cso30:c:Complex
cso30:i:CC_Cytoplasm
--
--
csml-variable:Double
m96
0
infinite
0
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c2 : 1
stoichiometry:c1 : 1
stoichiometry:c3 : 1
m2283*m5*0.1
nodelay
--
0
PMID: 17981503,15629253,15860371 They form heterodimers with the retinoid X receptor (RXR) and activate transcription by binding to a specific DNA element termed the PPAR response element (PPRE)
p10
p10
cso30:i:ME_UnknownDegradation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c24 : 1
stoichiometry:c25 : 1
stoichiometry:c26 : 1
m22*0.1
nodelay
--
0
PMID: 17981503 When LPS binds to TLR4, the NF-KappaB signaling pathway is activated, IKappaB is degraded, and NF-KappaB p65-p50 heterodimers enter the nucleus.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c27 : 1
stoichiometry:c28 : 1
m1617*0.1
nodelay
--
0
PMID: 17981503 When LPS binds to TLR4, the NF-KappaB signaling pathway is activated, IKappaB is degraded, and NF-KappaB p65-p50 heterodimers enter the nucleus.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c30 : 1
stoichiometry:c31 : 1
stoichiometry:c32 : 1
m18*m25*0.1
nodelay
--
0
PMID: 17981503 Concomitant with these events, the corepressor complex is ubiquitinated and degraded by the 19 S proteasome.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c33 : 1
stoichiometry:c34 : 1
m26*0.1
nodelay
--
0
PMID: 17981503 Concomitant with these events, the corepressor complex is ubiquitinated and degraded by the 19 S proteasome.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c35 : 1
stoichiometry:c36 : 1
stoichiometry:c37 : 1
m24*m19*0.1
nodelay
--
0
PMID: 17981503 NF-KappaB p65-p50 heterodimers bind to the KappaB element located in the iNOS promoter, facilitating the recruitment of coactivator complexes and activation of iNOS gene transcription.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c38 : 1
stoichiometry:c39 : 1
stoichiometry:c40 : 1
m29*m28*0.1
nodelay
--
0
PMID: 17981503 NF-KappaB p65-p50 heterodimers bind to the KappaB element located in the iNOS promoter, facilitating the recruitment of coactivator complexes and activation of iNOS gene transcription.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c41 : 1
stoichiometry:c42 : 1
m30*0.1
nodelay
--
0
PMID: 17981503 NF-KappaB p65-p50 heterodimers bind to the KappaB element located in the iNOS promoter, facilitating the recruitment of coactivator complexes and activation of iNOS gene transcription.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c49 : 1
stoichiometry:c50 : 1
stoichiometry:c51 : 1
m31*m18*0.1
nodelay
--
0
PMID: 17981503,16127449 The SUMOylated PPARgamma binds to NCoR and interferes with clearance of the corepressor complex, thereby maintaining the promoter in the repressed state
p18
p18
cso30:i:ME_Sumoylation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c43 : 1
stoichiometry:c44 : 1
stoichiometry:c46 : 1
stoichiometry:c47 : 1
stoichiometry:c48 : 1
stoichiometry:c45 : 1
m4499*m15*m20*m4500*m2460*0.1
nodelay
--
0
PMID: 17981503 In cells treated with PPARgamma ligand plus LPS, ligand binding triggers conjugation of a small fraction of cellular PPARgamma with SUMO1 (small ubiquitin-like modifier) on lysine 365 (K365), mediated by the SUMOylation pathway E2 ligase Ubc9 and E3 ligase PIAS1 PMID: 17981503 Figure 2
p19
p19
cso30:i:ME_Binding
cso30:i:CC_Nucleoplasm
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c52 : 1
stoichiometry:c53 : 1
stoichiometry:c55 : 1
stoichiometry:c54 : 1
m14*m2283*0.1
nodelay
--
0
PMID: 17981503 SUMOylation of PPARgamma is predicted to prevent its heterodimerization with RXR, thereby dedicating this form of PPARgamma to a repressor function.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c4 : 1
stoichiometry:c5 : 1
stoichiometry:c6 : 1
m2283*m11*0.1
nodelay
--
0
PMID: 17981503, 15629253, 15860371 They form heterodimers with the retinoid X receptor (RXR) and activate transcription by binding to a specific DNA element termed the PPAR response element (PPRE)
p20
p20
cso30:i:ME_GeneExpression
cso30:i:CC_Nucleoplasm
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c66 : 1
stoichiometry:c68 : 1
stoichiometry:c69 : 1
stoichiometry:c67 : 1
1.0*0.1
nodelay
--
0
PMID: 17981503,12970571 Binding of ligand to PPARdelta releases BCL-6, which then represses inflammatory-response genes PMID: 17981503,17218271 The liver X receptors (LXRalpha and -beta) repress a subset of inflammatory-response genes that overlaps with, yet is distinct from, the subset repressed by PPARgamma
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c56 : 1
stoichiometry:c57 : 1
stoichiometry:c58 : 1
m166*m5*0.1
nodelay
--
0
PMID: 17981503,10542237 Direct binding of PPARalpha to NF-KappaB p65 was demonstrated by in vitro assays, suggesting that transrepression might involve direct interference with transcriptional activation by NF-KappaB
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c59 : 1
stoichiometry:c60 : 1
stoichiometry:c61 : 1
m13276*m17*0.1
nodelay
--
0
PMID: 17981503 For PPARdelta, a novel mechanism for transrepression was identified that involves binding and sequestration of the transcriptional repressor BCL-6 by unliganded PPARdelta.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c62 : 1
stoichiometry:c63 : 1
stoichiometry:c64 : 1
stoichiometry:c65 : 1
m36*m16*0.1
nodelay
--
0
PMID: 17981503,12970571 Binding of ligand to PPARdelta releases BCL-6, which then represses inflammatory-response genes
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c70 : 1
stoichiometry:c71 : 1
stoichiometry:c72 : 1
m38*m40*0.1
nodelay
--
0
PMID: 17981503 Binding of ligand to the LXRs triggers covalent conjugation with SUMO2 and -3.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c73 : 1
stoichiometry:c74 : 1
stoichiometry:c75 : 1
m40*m39*0.1
nodelay
--
0
PMID: 17981503 Binding of ligand to the LXRs triggers covalent conjugation with SUMO2 and -3.
p26
p26
cso30:i:ME_Sumoylation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c76 : 1
stoichiometry:c77 : 1
stoichiometry:c78 : 1
stoichiometry:c79 : 1
stoichiometry:c80 : 1
stoichiometry:c81 : 1
m41*m43*m44*m4500*m20760*0.1
nodelay
--
0
PMID: 17981503 Binding of ligand to the LXRs triggers covalent conjugation with SUMO2 and -3 PMID: 17981503 Here, the E3 ligase is HDAC4 rather than PIAS1.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c82 : 1
stoichiometry:c83 : 1
stoichiometry:c84 : 1
m45*m18*0.1
nodelay
--
0
PMID: 17981503 As with PPARgamma, SUMOylated LXR interferes with clearance of NCoR-containing corepressor complexes from the promoters of target genes.
p26
p28
cso30:i:ME_Sumoylation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c85 : 1
stoichiometry:c86 : 1
stoichiometry:c87 : 1
stoichiometry:c88 : 1
stoichiometry:c89 : 1
stoichiometry:c90 : 1
m42*m44*m43*m20760*m4500*0.1
nodelay
--
0
PMID: 17981503 Binding of ligand to the LXRs triggers covalent conjugation with SUMO2 and -3 PMID: 17981503 Here, the E3 ligase is HDAC4 rather than PIAS1.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c91 : 1
stoichiometry:c92 : 1
stoichiometry:c93 : 1
m47*m18*0.1
nodelay
--
0
PMID: 17981503 As with PPARgamma, SUMOylated LXR interferes with clearance of NCoR-containing corepressor complexes from the promoters of target genes.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c7 : 1
stoichiometry:c8 : 1
stoichiometry:c9 : 1
m13*m14*0.1
nodelay
--
0
PMID: 17981503,12110006,17631136 For example, the PPAR¦Ã ligand troglitazone increased expression of the chemokine MCP-1 (CCL2) and enhanced monocyte/macrophage infiltration in a rat model of glomerulonephritis, and the PPAR¦Ä ligand GW0742 worsened the course of colitis in IL-10-deficient mice
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c94 : 1
stoichiometry:c95 : 1
stoichiometry:c96 : 1
stoichiometry:c99 : 1
m49*m6069*0.1
nodelay
--
0
PMID: 17981503,16127449,17072333 Ligand-bound GR interacts strongly with the p65 subunit of NF-KappaB, in contrast to ligand-bound PPARgamma, which interacts very weakly with p65
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c97 : 1
stoichiometry:c98 : 1
m166*m63*0.1
nodelay
--
0
PMID: 17981503,16127449,17072333 Ligand-bound GR interacts strongly with the p65 subunit of NF-KappaB, in contrast to ligand-bound PPARgamma, which interacts very weakly with p65
p32
p32
cso30:i:ME_GeneExpression
cso30:i:CC_Nucleoplasm
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c100 : 1
stoichiometry:c102 : 1
stoichiometry:c103 : 1
stoichiometry:c101 : 1
m175*m24*0.1
nodelay
--
0
PMID: 17981503,15879558 Interestingly, repression by GR of tumor necrosis factor (TNF)-stimulated gene transcription in A549 lung adenocarcinoma cells is also target-gene specific: some NF-KappaB-dependent genes such as IL-8 (CXCL8) are repressed, whereas others, such as IKappaBalpha, are not
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c104 : 1
stoichiometry:c105 : 1
stoichiometry:c106 : 1
m66*m5*0.1
nodelay
--
0
PMID: 17981503,10542237,14609950 In the case of AP-1, several mechanisms for transrepression by nuclear receptors have been identified, including inhibition of c-Jun N-terminal kinase (JNK) signaling by GR, and direct interaction of PPARalpha with c-Jun, resulting in interference with transcriptional activation
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c107 : 1
stoichiometry:c108 : 1
1.0*0.1
nodelay
--
0
PMID: 17981503,12133943,17475839,17277116 PPARgamma ligands inhibit DC maturation and repress the expression by DC of CD1a, CD40, CD83, CCR7, and the costimulatory molecule CD80 (B7.1)
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c109 : 1
stoichiometry:c110 : 1
1.0*0.1
nodelay
--
0
PMID: 17981503,12133943,17475839,17277116 PPARgamma ligands inhibit DC maturation and repress the expression by DC of CD1a, CD40, CD83, CCR7, and the costimulatory molecule CD80 (B7.1)
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c111 : 1
stoichiometry:c112 : 1
1.0*0.1
nodelay
--
0
PMID: 17981503,12133943,17475839,17277116 PPARgamma ligands inhibit DC maturation and repress the expression by DC of CD1a, CD40, CD83, CCR7, and the costimulatory molecule CD80 (B7.1)
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c113 : 1
stoichiometry:c114 : 1
1.0*0.1
nodelay
--
0
PMID: 17981503,12133943,17475839,17277116 PPARgamma ligands inhibit DC maturation and repress the expression by DC of CD1a, CD40, CD83, CCR7, and the costimulatory molecule CD80 (B7.1)
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c115 : 1
stoichiometry:c119 : 1
stoichiometry:c116 : 1
m68*0.1
nodelay
--
0
PMID: 17981503,12133943,17192567 PPARgamma ligands also repress DC production of IL-12 and several chemokines, including CXCL10 and RANTES
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c117 : 1
stoichiometry:c120 : 1
stoichiometry:c118 : 1
m95041*0.1
nodelay
--
0
PMID: 17981503,12133943,17192567 PPARgamma ligands also repress DC production of IL-12 and several chemokines, including CXCL10 and RANTES
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c10 : 1
stoichiometry:c11 : 1
m15*0.1
nodelay
--
0
PMID: 17981503,12110006,17631136 For example, the PPARgamma ligand troglitazone increased expression of the chemokine MCP-1 (CCL2) and enhanced monocyte/macrophage infiltration in a rat model of glomerulonephritis, and the PPARdelta ligand GW0742 worsened the course of colitis in IL-10-deficient mice
p38
p40
cso30:i:ME_Translation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c121 : 1
stoichiometry:c123 : 1
stoichiometry:c122 : 1
m93487*0.1
nodelay
--
0
PMID: 17981503,12133943,17192567 PPARgamma ligands also repress DC production of IL-12 and several chemokines, including CXCL10 and RANTES
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c124 : 1
stoichiometry:c125 : 1
stoichiometry:c126 : 1
m5*m70*0.1
nodelay
--
0
PMID: 17981503,11934839 The PPARalpha ligand fenofibrate represses IFNgamma expression in anti-CD3-treated cultured human CD4+ lymphocytes
p42
p42
cso30:i:ME_GeneExpression
cso30:i:CC_Nucleoplasm
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c127 : 1
stoichiometry:c132 : 1
stoichiometry:c128 : 1
1.0*0.1
nodelay
--
0
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c129 : 1
stoichiometry:c130 : 1
stoichiometry:c131 : 1
m72*m5*0.1
nodelay
--
0
PMID: 17981503,11884448 Similarly, another PPARalpha ligand, Wy14643, represses IFNgamma in activated mouse splenocytes
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c133 : 1
stoichiometry:c134 : 1
1.0*0.1
nodelay
--
0
PMID: 17981503,17631136 More recently, fenofibrate has been shown to repress IL-17 expression in cultured splenocytes activated by PMA plus ionomycin and by Th17 cells in a pathogenic CD4+ T-cell line cultured from C3H Bir mice treated with cecal bacterial antigens
p45
p45
cso30:i:ME_GeneExpression
cso30:i:CC_NuclearEnvelopeLumen
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c139 : 1
stoichiometry:c136 : 1
m230*0.1
nodelay
--
0
PMID: 17981503 Expression of the adhesion molecules ICAM-1, and -2, and VCAM-1 is induced by proinflammatory cytokines, including TNFalpha. PMID: 17981503,10377075,16115476,16439686 PPARalpha is expressed in vascular endothelial cells, and PPARalpha ligands repress TNFalpha-elicited expression of VCAM-1 by these cells
p45
p46
cso30:i:ME_GeneExpression
cso30:i:CC_NuclearEnvelopeLumen
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c140 : 1
stoichiometry:c138 : 1
m230*0.1
nodelay
--
0
PMID: 17981503 Expression of the adhesion molecules ICAM-1, and -2, and VCAM-1 is induced by proinflammatory cytokines, including TNFalpha. PMID: 17981503,10377075,16115476,16439686 PPARalpha is expressed in vascular endothelial cells, and PPARalpha ligands repress TNFalpha-elicited expression of VCAM-1 by these cells
p45
p47
cso30:i:ME_GeneExpression
cso30:i:CC_NuclearEnvelopeLumen
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c135 : 1
stoichiometry:c141 : 1
stoichiometry:c137 : 1
m230*0.1
nodelay
--
0
PMID: 17981503 Expression of the adhesion molecules ICAM-1, and -2, and VCAM-1 is induced by proinflammatory cytokines, including TNFalpha. PMID: 17981503,10377075,16115476,16439686 PPARalpha is expressed in vascular endothelial cells, and PPARalpha ligands repress TNFalpha-elicited expression of VCAM-1 by these cells
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c142 : 1
stoichiometry:c143 : 1
m840*0.1
nodelay
--
0
PMID: 17981503,16798734 Interestingly, the proinflammatory cytokine IL-17 induces CXCL8 gene transcription and also stabilizes CXCL8 mRNA via a p38 MAP kinase-dependent pathway
p51
p49
cso30:i:ME_GeneExpression
cso30:i:CC_Nucleoplasm
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c144 : 1
stoichiometry:c155 : 1
stoichiometry:c154 : 1
m20*0.1
nodelay
--
0
PMID: 17981503,16143103 In a recent microarray survey of genes highly induced by LPS in mouse macrophages, the PPARgamma ligand GW7845 repressed expression of several chemokine genes, including those encoding CXCL1, -9, and -10 as well as CCL2, -4, -7, -12, -17, and -19, by >40%. PMID: 17981503,17486092 For example, in chronic inflammatory diseases perpetuated by effector T cells, activated Th1 cells are attracted to the site of inflammation by chemokines that interact with the CXCR3 receptor, including CXCL9, -10, and -11 PMID: 17981503,11208713 Expression of these chemokines is highly induced by the combination of IFNgamma and TNFalpha
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c12 : 1
stoichiometry:c13 : 1
m16*m17*0.1
nodelay
--
0
PMID: 17981503,12110006,17631136 For example, the PPARgamma ligand troglitazone increased expression of the chemokine MCP-1 (CCL2) and enhanced monocyte/macrophage infiltration in a rat model of glomerulonephritis, and the PPAR¦Ä ligand GW0742 worsened the course of colitis in IL-10-deficient mice
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c145 : 1
stoichiometry:c146 : 1
stoichiometry:c147 : 1
m77*m14*0.1
nodelay
--
0
PMID: 17981503,16143103 In a recent microarray survey of genes highly induced by LPS in mouse macrophages, the PPARgamma ligand GW7845 repressed expression of several chemokine genes, including those encoding CXCL1, -9, and -10 as well as CCL2, -4, -7, -12, -17, and -19, by >40%.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c148 : 1
stoichiometry:c153 : 1
stoichiometry:c149 : 1
m20*0.1
nodelay
--
0
PMID: 17981503,16143103 In a recent microarray survey of genes highly induced by LPS in mouse macrophages, the PPARgamma ligand GW7845 repressed expression of several chemokine genes, including those encoding CXCL1, -9, and -10 as well as CCL2, -4, -7, -12, -17, and -19, by >40%.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c150 : 1
stoichiometry:c152 : 1
stoichiometry:c151 : 1
m20*0.1
nodelay
--
0
PMID: 17981503,16143103 In a recent microarray survey of genes highly induced by LPS in mouse macrophages, the PPARgamma ligand GW7845 repressed expression of several chemokine genes, including those encoding CXCL1, -9, and -10 as well as CCL2, -4, -7, -12, -17, and -19, by >40%.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c156 : 1
stoichiometry:c158 : 1
stoichiometry:c157 : 1
m20*0.1
nodelay
--
0
PMID: 17981503,16143103 In a recent microarray survey of genes highly induced by LPS in mouse macrophages, the PPARgamma ligand GW7845 repressed expression of several chemokine genes, including those encoding CXCL1, -9, and -10 as well as CCL2, -4, -7, -12, -17, and -19, by >40%.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c160 : 1
stoichiometry:c161 : 1
stoichiometry:c159 : 1
m20*0.1
nodelay
--
0
PMID: 17981503,16143103 In a recent microarray survey of genes highly induced by LPS in mouse macrophages, the PPARgamma ligand GW7845 repressed expression of several chemokine genes, including those encoding CXCL1, -9, and -10 as well as CCL2, -4, -7, -12, -17, and -19, by >40%.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c162 : 1
stoichiometry:c163 : 1
stoichiometry:c164 : 1
m20*0.1
nodelay
--
0
PMID: 17981503,16143103 In a recent microarray survey of genes highly induced by LPS in mouse macrophages, the PPARgamma ligand GW7845 repressed expression of several chemokine genes, including those encoding CXCL1, -9, and -10 as well as CCL2, -4, -7, -12, -17, and -19, by >40%.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c166 : 1
stoichiometry:c167 : 1
stoichiometry:c165 : 1
m20*0.1
nodelay
--
0
PMID: 17981503,16143103 In a recent microarray survey of genes highly induced by LPS in mouse macrophages, the PPARgamma ligand GW7845 repressed expression of several chemokine genes, including those encoding CXCL1, -9, and -10 as well as CCL2, -4, -7, -12, -17, and -19, by >40%.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c168 : 1
stoichiometry:c170 : 1
stoichiometry:c169 : 1
m20*0.1
nodelay
--
0
PMID: 17981503,16143103 In a recent microarray survey of genes highly induced by LPS in mouse macrophages, the PPARgamma ligand GW7845 repressed expression of several chemokine genes, including those encoding CXCL1, -9, and -10 as well as CCL2, -4, -7, -12, -17, and -19, by >40%.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c172 : 1
stoichiometry:c173 : 1
stoichiometry:c171 : 1
m20*0.1
nodelay
--
0
PMID: 17981503,16143103 In a recent microarray survey of genes highly induced by LPS in mouse macrophages, the PPARgamma ligand GW7845 repressed expression of several chemokine genes, including those encoding CXCL1, -9, and -10 as well as CCL2, -4, -7, -12, -17, and -19, by >40%.
p59
p59
cso30:i:ME_GeneExpression
cso30:i:CC_Nucleoplasm
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c174 : 1
stoichiometry:c179 : 1
stoichiometry:c175 : 1
1.0*0.1
nodelay
--
0
PMID: 17981503,17631136 The PPARalpha ligands fenofibrate and GW7647 also repress CXCL10 mRNA expression and promoter activity in human HT-29 cells, a model for colonic epithelial cells
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c29 : 1
stoichiometry:c15 : 1
m20*0.1
nodelay
--
0
PMID:17981503,16127449 Repression of lipopolysaccharide (LPS)-induced iNOS (NOS2) gene expression in macrophages has been characterized in detail
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c176 : 1
stoichiometry:c177 : 1
stoichiometry:c178 : 1
m5*m86*0.1
nodelay
--
0
PMID: 17981503,17631136 The PPARalpha ligands fenofibrate and GW7647 also repress CXCL10 mRNA expression and promoter activity in human HT-29 cells, a model for colonic epithelial cells
p61
p61
cso30:i:ME_Binding
cso30:i:CC_Extracellular
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c181 : 1
stoichiometry:c182 : 1
stoichiometry:c183 : 1
m69*m4372*0.1
nodelay
--
0
PMID: 17981503,17486092 For example, in chronic inflammatory diseases perpetuated by effector T cells, activated Th1 cells are attracted to the site of inflammation by chemokines that interact with the CXCR3 receptor, including CXCL9, -10, and -11
p51
p62
cso30:i:ME_GeneExpression
cso30:i:CC_Nucleoplasm
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c180 : 1
stoichiometry:c184 : 1
stoichiometry:c185 : 1
m230*m20*0.1
nodelay
--
0
PMID: 17981503,17486092 For example, in chronic inflammatory diseases perpetuated by effector T cells, activated Th1 cells are attracted to the site of inflammation by chemokines that interact with the CXCR3 receptor, including CXCL9, -10, and -11 PMID: 17981503,11208713 Expression of these chemokines is highly induced by the combination of IFNgamma and TNFalpha
p51
p63
cso30:i:ME_GeneExpression
cso30:i:CC_Nucleoplasm
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c187 : 1
stoichiometry:c188 : 1
stoichiometry:c186 : 1
m230*m20*0.1
nodelay
--
0
PMID: 17981503,11208713 Expression of these chemokines is highly induced by the combination of IFNgamma and TNFalpha
p61
p64
cso30:i:ME_Binding
cso30:i:CC_Extracellular
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c189 : 1
stoichiometry:c190 : 1
stoichiometry:c191 : 1
m4372*m89*0.1
nodelay
--
0
PMID: 17981503,17486092 For example, in chronic inflammatory diseases perpetuated by effector T cells, activated Th1 cells are attracted to the site of inflammation by chemokines that interact with the CXCR3 receptor, including CXCL9, -10, and -11
p51
p65
cso30:i:ME_GeneExpression
cso30:i:CC_Nucleoplasm
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c193 : 1
stoichiometry:c194 : 1
stoichiometry:c192 : 1
m230*m20*0.1
nodelay
--
0
PMID: 17981503,11208713 Expression of these chemokines is highly induced by the combination of IFNgamma and TNFalpha
p61
p66
cso30:i:ME_Binding
cso30:i:CC_Extracellular
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c195 : 1
stoichiometry:c196 : 1
stoichiometry:c197 : 1
m4372*m92*0.1
nodelay
--
0
PMID: 17981503,17486092 For example, in chronic inflammatory diseases perpetuated by effector T cells, activated Th1 cells are attracted to the site of inflammation by chemokines that interact with the CXCR3 receptor, including CXCL9, -10, and -11
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c199 : 1
stoichiometry:c198 : 1
1.0*0.1
nodelay
--
0
PMID: 17981503 PPARgamma then represses expression of the inflammatory-response gene Egr-1.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c201 : 1
stoichiometry:c200 : 1
m94*0.1
nodelay
--
0
PMID: 17981503,16713977 Recently, suppression of the inflammatory response by CO in macrophages has been ascribed to a CO-mediated burst of reactive oxygen species, which induce the expression of PPARgamma
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c202 : 1
stoichiometry:c203 : 1
m95*0.1
nodelay
--
0
PMID: 17981503,16713977 Recently, suppression of the inflammatory response by CO in macrophages has been ascribed to a CO-mediated burst of reactive oxygen species, which induce the expression of PPARgamma
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c17 : 1
stoichiometry:c18 : 1
stoichiometry:c16 : 1
m19*0.1
nodelay
--
0
PMID: 17981503 In the ¡Èoff¡É state, the iNOS gene is actively repressed by a multisubunit complex containing NCoR, histone deacetylase 3 (HDAC3), TBL1, and TBLR1.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c204 : 1
stoichiometry:c205 : 1
stoichiometry:c206 : 1
m564*m17*0.1
nodelay
--
0
PMID: 17981503,16943204 Recent studies have demonstrated that PPARdelta binds to ERK5 and is required for ERK5-mediated repression of NF-KappaB
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c14 : 1
stoichiometry:c19 : 1
stoichiometry:c20 : 1
m155666*m3961*0.1
nodelay
--
0
PMID: 17981503 When LPS binds to TLR4, the NF-KappaB signaling pathway is activated, IKappaB is degraded, and NF-KappaB p65-p50 heterodimers enter the nucleus.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c21 : 1
stoichiometry:c22 : 1
stoichiometry:c23 : 1
m20*m21*0.1
nodelay
--
0
PMID: 17981503 When LPS binds to TLR4, the NF-KappaB signaling pathway is activated, IKappaB is degraded, and NF-KappaB p65-p50 heterodimers enter the nucleus.
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--